Apyx Medical Corporation (NASDAQ:APYX) Stock Has Consensus Target Price of $6.60

Shares of Apyx Medical Corporation (NASDAQ:APYX) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.

Several research analysts have issued reports on APYX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Zacks Research upgraded Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th. HC Wainwright assumed coverage on Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Maxim Group initiated coverage on Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price target on the stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Nwam LLC acquired a new stake in shares of Apyx Medical during the 1st quarter worth approximately $47,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Apyx Medical during the second quarter worth approximately $62,000. AXQ Capital LP acquired a new position in Apyx Medical in the second quarter valued at approximately $78,000. Jefferies Financial Group Inc. acquired a new position in Apyx Medical in the second quarter valued at approximately $110,000. Finally, Squarepoint Ops LLC bought a new position in Apyx Medical in the second quarter valued at approximately $144,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Stock Up 2.0%

Shares of NASDAQ:APYX opened at $2.55 on Friday. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19. The firm has a market cap of $107.41 million, a P/E ratio of -12.75 and a beta of 1.45. Apyx Medical has a 12 month low of $2.07 and a 12 month high of $5.08. The company’s 50-day moving average price is $3.19 and its two-hundred day moving average price is $3.72.

Apyx Medical (NASDAQ:APYX) last announced its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The company had revenue of $13.88 million for the quarter, compared to analyst estimates of $13.18 million. As a group, research analysts forecast that Apyx Medical will post -0.25 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets energy-based surgical products. The company focuses on systems that use its proprietary Helium Plasma technology to support tissue cutting, coagulation and soft-tissue procedures.

Apyx Medical’s product portfolio includes the Renuvion system, which is used in surgical and aesthetic procedures, and J-Plasma, an earlier generation of its Helium Plasma technology. Its products are marketed for use in fields such as plastic and cosmetic surgery, general surgery and other soft-tissue applications.

The company was formerly known as Bovie Medical Corporation and adopted the Apyx Medical name in 2018.